Companies · Biotechnology

Allocure Inc

BURLINGTON · Biotechnology

Diligence memoA one-page analyst read on Allocure Inc — recommendation, valuation, rhythm, risks.
$50.5M
Total raised · real
5
Rounds
0.6×
Latest step-up
Top 19%
Sector rank · raised
Series B
Latest stage · inferred · Thu Mar 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Allocure Inc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.61× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era.
Dormant
  • Last raise 14.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Allocure Inc is one of 4291 Biotechnology companies tracked from BURLINGTON. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BPre-Seed · 2009-06-25 Raised $400K (real) Modeled valuation $22M (est)$400K$22MPre-Seed2009Series A · 2009-11-05 Raised $5.6M (real) Modeled valuation $202M (est)$5.6M$202MSeries A2009Series A · 2011-09-30 Raised $1.5M (real) Modeled valuation $54M (est)$1.5M$54MSeries A2011Series B · 2012-03-29 Raised $27M (real) Modeled valuation $1.1B (est)$27M$1.1BSeries B2012Series B · 2012-03-29 Raised $17M (real) Modeled valuation $655M (est)$17M$655MSeries B2012+$5.6M+$1.5M+$27M+$17MCumulative $50M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$400K · 2009
Series A$5.6M · 2009no Seed on file
Series A extension$1.5M · 2011
Series B$26.5M · 2012
Series B extension$16.5M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$1.1B
Base estimate est.
$53.0M
Conservative case
$4.0B
Upside case
$147.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $22.1M · 2009-06-252009Series A · modeled $202.0M · 2009-11-05Series A · modeled $54.3M · 2011-09-30Series B · modeled $1.1B · 2012-03-29Series B · modeled $654.9M · 2012-03-292012
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
14.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
8 mo
Avg between rounds
$18.3M/yr
Capital velocity
17.0 yr
On record since
2009
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.0× above median
This company$50.5M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.9× of median
This company$16.5M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 16× above median
This company$1.1B
Sector median$64.2M

Raised more than 82% of sector peers (real $). Modeled value above 90% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 48.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Redpoint Bio CORP · Series B Raised $40.0M · modeled $1.6B (est)Cardiaq Valve Technologies Inc · Series B Raised $77.2M · modeled $1.5B (est)Visterra, Inc. · Series B Raised $82.4M · modeled $1.4B (est)Celltex Therapeutics Corp · Series B Raised $34.1M · modeled $1.4B (est)Crown Bioscience, Inc · Series B Raised $87.1M · modeled $1.2B (est)Trius Therapeutics Inc · Series B Raised $49.3M · modeled $1.2B (est)Intercept Pharmaceuticals Inc · Series B Raised $45.0M · modeled $1.2B (est)Crescendo Bioscience, Inc. · Series B Raised $169.8M · modeled $1.1B (est)Pathwork Diagnostics Inc · Series B Raised $52.5M · modeled $1.0B (est)MethylGene Inc. · Series B Raised $97.2M · modeled $1.0B (est)Predictive Biosciences, Inc · Series B Raised $26.8M · modeled $1.0B (est)Allocure Inc (this company) Raised $50.5M · modeled $1.1B (est)Allocure Inc
CompanyStageRaised · realValue · estvs peer med.
Redpoint Bio CORPSeries B$40.0M$1.6B2.44×
Cardiaq Valve Technologies IncSeries B$77.2M$1.5B2.27×
Visterra, Inc.Series B$82.4M$1.4B2.08×
Celltex Therapeutics CorpSeries B$34.1M$1.4B2.07×
Crown Bioscience, IncSeries B$87.1M$1.2B1.86×
Trius Therapeutics IncSeries B$49.3M$1.2B1.84×
Intercept Pharmaceuticals IncSeries B$45.0M$1.2B1.83×
Crescendo Bioscience, Inc.Series B$169.8M$1.1B1.73×
Allocure Inc this companySeries B$50.5M$1.1B1.61×
Pathwork Diagnostics IncSeries B$52.5M$1.0B1.60×
MethylGene Inc.Series B$97.2M$1.0B1.59×
Predictive Biosciences, IncSeries B$26.8M$1.0B1.55×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$400K2009-06-25$2.2M$22.1M90%
Series A$5.6M2009-11-05$25.4M$202.0M90%
Series A$1.5M2011-09-30$6.8M$54.3M90%
Series B$26.5M2012-03-29$147.2M$1.1B90%
Series B$16.5M2012-03-29$91.7M$654.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$400K2009-06-25
    • First recorded raise — entered as Pre-Seed.
  2. Series A$5.6M2009-11-05
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 14.0× larger than the prior — scaling up.
  3. Series A$1.5M2011-09-30
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 3.7× smaller than the prior — bridge or down round.
  4. Series B$26.5M2012-03-29
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 17.6× larger than the prior — scaling up.
  5. Series B$16.5M2012-03-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× smaller than the prior — bridge or down round.
Intelligence
2012 ~Q4
Modeled next raise · ~8mo cadence
$16.5M
Modeled next size est.range $16.5M$26.4M
0.6×
Last step-up
$18.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Lutz Giebel5 other2009-06
Mette Kirstine Agger5 other2012-03
Christof Westenfelder1 other2009-06
David Kirstine Guyer2012-03
George M. Eldridge2011-09
John B. Wirthlin2011-09
John Wirthlin2009-06
Kevin J. Heyeck2011-09
Lutz B. Giebel2011-09
Robert M Brenner2011-09
Scott Kirstine Canute2012-03
Thomas B. Dyrberg2011-09
Thomas Dryberg2009-06
Registry & provenance

Allocure Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1439955
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Logical Therapeutics IncBiotechnologySeries B$42.5M$396.9Mnetwork1 shared operator · same sector · same stage
Lux Biosciences IncBiotechnologySeries B$81.1M$635.0Mnetwork1 shared operator · same sector · same stage
Good Start Genetics, Inc.BiotechnologySeries B$28.2M$396.9Mnetwork1 shared operator · same sector · same stage
PanOptica, Inc.BiotechnologySeries C$57.3M$1.7Bnetwork1 shared operator · same sector
Applied Proteomics, Inc.BiotechnologySeries B$50.4M$1.1Bsame sector · same stage
Molecular Assemblies, Inc.BiotechnologySeries B$50.8M$618.8Msame sector · same stage
Noetic US Holdings LLCBiotechnologySeries B$50.1M$718.8Msame sector · same stage
SentreHEART IncBiotechnologySeries B$51.0M$992.2Msame sector · same stage
Frequently asked
How much funding has Allocure Inc raised?
Allocure Inc has raised approximately $50.5M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Allocure Inc's estimated valuation?
Provath's modeled valuation for Allocure Inc is approximately $1.1B (modeled range $53.0M–$4.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Allocure Inc at?
Allocure Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Thu Mar 29.
What does Allocure Inc do and where is it based?
Allocure Inc operates in the Biotechnology sector, based in BURLINGTON.
Explore related

See where Allocure Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Allocure Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.